Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Acinetobacter baumannii has been recognized as a cause of nosocomial infection. To date, polymyxins, the last-resort therapeutic agents for carbapenem-resistant A. baumannii (CRAB). Thus, the small number of effective antibiotic options against CRAB represents a challenge to human health. This study examined the appropriate dosage regimens of colistin alone or in combination with sulbactam or fosfomycin using Monte Carlo simulation with the aims of improving efficacy and reducing the risk of nephrotoxicity. Materials and Methods: Clinical CRAB isolates were obtained from patients admitted to Phramongkutklao Hospital in 2014 and 2015. The minimum inhibitory concentration (MIC) of colistin for each CRAB isolate was determined using the broth dilution method, whereas those of sulbactam and fosfomycin were determined using the agar dilution method. Each drug regimen was simulated using the Monte Carlo technique to calculate the probability of target attainment (PTA) and the cumulative fraction of response (CFR). Nephrotoxicity based on RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria was indicated by colistin trough concentration exceeding ≥3.3 µg/mL. Results: A total of 50 CRAB isolates were included. The MIC50 and MIC90 were 64 and 128 µg/mL, respectively, for sulbactam, 256 and 2,048 µg/mL, respectively, for fosfomycin, and 1 and 4 µg/mL, respectively, for colistin. In patients with creatinine clearance of 91 – 130 m/min, the dosing regimens of 180 mg every 12 h and 150 mg every 8 h achieved ≥ 90% of target of the area under the free drug plasma concentration–time curve from 0 to 24 hr (fAUC24)/MIC ≥25 against isolates MICs of ≤0.25 and ≤0.5 µg/mL, respectively, and their rates of colistin trough concentration more than ≥3.3 µg/mL were 35 and 54%, respectively. Colistin combined with sulbactam or fosfomycin decreased the colistin MIC of CRAB isolates from 1 – 16 µg/mL to 0.0625 – 1 and 0.0625 – 2 µg/mL, respectively. Based on CFR ≥ 90%, no colistin monotherapy regimens in patients with creatinine clearance of 91 – 130 mL/min were effective against all of the studied CRAB isolates. For improving efficacy and reducing the risk of nephrotoxicity, colistin 150 mg given every 12 h together with sulbactam (≥6 g/day) or fosfomycin (≥18 g/day) was effective in patients with creatinine clearance of 91 – 130 mL/min. Additionally, both colistin combination regimens were effective against five colistin-resistant A. baumannii isolates. Conclusion: Colistin monotherapy at the maximum recommended dose might not cover some CRAB isolates. Colistin combination therapy appears appropriate for achieving the pharmacokinetic/pharmacodynamic targets of CRAB treatment.
Abstract
Background: Acinetobacter baumannii has been recognized as a cause of nosocomial infection. To date, polymyxins, the last-resort therapeutic agents for carbapenem-resistant A. baumannii (CRAB). Thus, the small number of effective antibiotic options against CRAB represents a challenge to human health. This study examined the appropriate dosage regimens of colistin alone or in combination with sulbactam or fosfomycin using Monte Carlo simulation with the aims of improving efficacy and reducing the risk of nephrotoxicity. Materials and Methods: Clinical CRAB isolates were obtained from patients admitted to Phramongkutklao Hospital in 2014 and 2015. The minimum inhibitory concentration (MIC) of colistin for each CRAB isolate was determined using the broth dilution method, whereas those of sulbactam and fosfomycin were determined using the agar dilution method. Each drug regimen was simulated using the Monte Carlo technique to calculate the probability of target attainment (PTA) and the cumulative fraction of response (CFR). Nephrotoxicity based on RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria was indicated by colistin trough concentration exceeding ≥3.3 µg/mL. Results: A total of 50 CRAB isolates were included. The MIC50 and MIC90 were 64 and 128 µg/mL, respectively, for sulbactam, 256 and 2,048 µg/mL, respectively, for fosfomycin, and 1 and 4 µg/mL, respectively, for colistin. In patients with creatinine clearance of 91 – 130 m/min, the dosing regimens of 180 mg every 12 h and 150 mg every 8 h achieved ≥ 90% of target of the area under the free drug plasma concentration–time curve from 0 to 24 hr (fAUC24)/MIC ≥25 against isolates MICs of ≤0.25 and ≤0.5 µg/mL, respectively, and their rates of colistin trough concentration more than ≥3.3 µg/mL were 35 and 54%, respectively. Colistin combined with sulbactam or fosfomycin decreased the colistin MIC of CRAB isolates from 1 – 16 µg/mL to 0.0625 – 1 and 0.0625 – 2 µg/mL, respectively. Based on CFR ≥ 90%, no colistin monotherapy regimens in patients with creatinine clearance of 91 – 130 mL/min were effective against all of the studied CRAB isolates. For improving efficacy and reducing the risk of nephrotoxicity, colistin 150 mg given every 12 h together with sulbactam (≥6 g/day) or fosfomycin (≥18 g/day) was effective in patients with creatinine clearance of 91 – 130 mL/min. Additionally, both colistin combination regimens were effective against five colistin-resistant A. baumannii isolates. Conclusion: Colistin monotherapy at the maximum recommended dose might not cover some CRAB isolates. Colistin combination therapy appears appropriate for achieving the pharmacokinetic/pharmacodynamic targets of CRAB treatment.
참고문헌 (29)
- Ramirez MS, "Carbapenemases: Transforming Acinetobacter baumannii into a yet more dangerous menace", Biomolecules, 10, pp.720~ (2020)
- Santimaleeworagun W, "The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia", J Appl Pharm Sci, 10, pp.056~059 (2020)
- Lertsrisatit Y, "In vitro activity of colistin monoand combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital", Infect Drug Resist, 10, pp.437~443 (2017)
- "Thailand (NARST)"[URL]
- Santimaleeworagun W, "In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases", Southeast Asian J Trop Med Public Health, 42, pp.890~900 (2011)
- Leelasupasri S, "Antimicrobial susceptibility among colistin, sulbactam, and fosfomycin and a synergism study of colistin in combination with sulbactam or fosfomycin against Clinical isolates of carbapenem-resistant Acinetobacter baumannii", J Pathogens, 2018, pp.3893492~ (2018)
- Jitaree K, "Pharmacokinetic", pharmacodynamic (PK, Antibiotics (Basel), pp.2019, 8[DOI]
- Sorli L, "Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study", MC Infect Dis, 13, pp.380~ (2013)
- Saelim W, "Pharmacodynamic profiling of optimal sulbactam regimens against carbapenem-resistant Acinetobacter baumannii for critically ill patients", Asian Pac J Trop Biomed, 8, pp.14~18 (2018)
- Tsuji BT, "International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)", Pharmacotherapy, 39, pp.10~39 (2019)
- Vardakas KZ, "Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis", Int J Antimicrob Agents, 51, pp.535~547 (2018)
- Vila J, "Therapeutic options for Acinetobacter baumannii infections: an update", Expert Opin Pharmacother, 13, pp.2319~2336 (2012)
- Betrosian AP, "High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii", Scand J Infect Dis, 39, pp.38~43 (2007)
- Shorr AF, "Intravenous fosfomycin for the treatment of hospitalized patients with serious infections", Expert Rev Anti Infect Ther, 15, pp.935~945 (2017)
- Clinical and Laboratory Standards Institute (CLSI), "Performance standards for antimicrobial susceptibility testing: Twenty-ninth informational supplement" (2019), CLSI
- "Clinical breakpoint tables for interpretation of MICs and zone diameters Version 10, 2019"[URL]
- Garonzik SM, "Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients", Antimicrob Agents Chemother, 55, pp.3284~3294 (2011)
- aruratanasirikul S, "Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused by Acinetobacter baumannii", Antimicrob Agents Chemother, 60, pp.7236~7244 (2016)
- Parker SL, "Population pharmacokinetics of fosfomycin in critically ill patients", Antimicrob Agents Chemother, 59, pp.6471~6476 (2015)
- Asín-Prieto E, "Applications of the pharmacokinetic", pharmacodynamic (PK, J Infect Chemother, pp.2015, 21[DOI]
- Dudhani RV, "fAUC", MIC is the most predictive pharmacokinetic, J Antimicrob Chemother, pp.2010, 65[DOI]
- . Jaruratanasirikul S, "Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii", Eur J Pharm Sci, 136, pp.104940~ (2019)
- Betrosian AP, "Efficacy and safety of high-dose ampicillin", sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, 2008, pp.56, 432~436
- Tsegka KG, "Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence", Expert Rev Anti Infect Ther, 18, pp.657~668 (2020)
- Kanchanasurakit Sukrit, "Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection", Infection and Chemotherapy, 52(4), pp.516~529 (2020), 대한감염학회[DOI]
- Zusman O, "Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis", J Antimicrob Chemother, 72, pp.29~39 (2017)
- Kengkla K, "Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis", J Antimicrob Chemother, 73, pp.22~32 (2018)
- Sirijatuphat R, "Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections", Antimicrob Agents Chemother, 58, pp.5598~5601 (2014)
- Santimaleeworagun W, "Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against VancomycinResistant Enterococci Infection", Antibiotics (Basel), 8, pp.245~ (2019)